NFKB1 and neoplasm: Lastly, the use of a metabolic product of estrogen, 2-Methoxyestradiol (2-ME), has shown to be effective in inhibiting NF-κB and therefore reducing the appearance of adaptive resistance in different tumor types (153–155).